{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:05:26Z","timestamp":1789175126067,"version":"build-2803163510"},"update-to":[{"DOI":"10.1371\/journal.pntd.0012011","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000}}],"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MCIN\/AEI","award":["AGL2017-83326-R"],"award-info":[{"award-number":["AGL2017-83326-R"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"crossref","award":["A way of making Europe"],"award-info":[{"award-number":["A way of making Europe"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"MCIN\/AEI","award":["PdC2021-121717-I00"],"award-info":[{"award-number":["PdC2021-121717-I00"]}]},{"name":"European Union Next Generation EU\/PRTR"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Rift Valley fever (RVF) is an important zoonotic viral disease affecting several species of domestic and wild ruminants, causing major economic losses and dozens of human deaths in various geographical areas of Africa, where it is endemic. Although it is not present in Europe, there is a risk of its introduction and spread linked to globalisation and climate change. At present, the only measure that could help to prevent the disease is vaccination of flocks in areas at risk of RVF. Available live attenuated vaccines are an effective means of controlling the disease, but their use is often questioned due to residual virulence, particularly in susceptible hosts such as pregnant sheep. On the other hand, no vaccine is currently licensed for use in humans. The development of safe and effective vaccines is therefore a major area of research. In previous studies, we selected under selective mutagenic pressure a highly attenuated RVFV 56\/74 virus variant called 40Fp8. This virus showed an extremely attenuated phenotype in both wild-type and immunodeficient A129 (IFNARKO) mice, yet was still able to induce protective immunity after a single inoculation, thus supporting its use as a safe, live attenuated vaccine. To further investigate its safety, in this work we have analysed the attenuation level of 40Fp8 in immunosuppressed mice (A129) when administered by the intranasal route, and compared it with other attenuated RVF viruses that are the basis of vaccines in use or in development. Our results show that 40Fp8 has a much higher attenuated level than these other viruses and confirm its potential as a candidate for safe RVF vaccine development.<\/jats:p>","DOI":"10.1371\/journal.pntd.0012011","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:11:07Z","timestamp":1724076667000},"page":"e0012011","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Rift Valley fever (RVF) vaccine candidate 40Fp8 shows an extreme attenuation in IFNARKO mice following intranasal inoculation"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-9166","authenticated-orcid":true,"given":"Bel\u00e9n","family":"Borrego","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"de la Losa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Jos\u00e9","family":"S\u00e1nchez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Brun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"7","key":"pntd.0012011.ref001","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2460\/javma.234.7.883","article-title":"Rift Valley fever virus","volume":"234","author":"BH Bird","year":"2009","journal-title":"J Am Vet Med Assoc"},{"issue":"6","key":"pntd.0012011.ref002","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/0035-9203(79)90006-3","article-title":"Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness","volume":"73","author":"LW Laughlin","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"2 Suppl","key":"pntd.0012011.ref003","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4269\/ajtmh.2010.09-0318","article-title":"Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in Tanzania, 2007","volume":"83","author":"M Mohamed","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0012011.ref004","doi-asserted-by":"crossref","first-page":"e0003548","DOI":"10.1371\/journal.pntd.0003548","article-title":"Factors associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya.","volume":"9","author":"AD LaBeaud","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0012011.ref005","doi-asserted-by":"crossref","first-page":"e0010233","DOI":"10.1371\/journal.pntd.0010233","article-title":"Clinical manifestations of Rift Valley fever in humans: Systematic review and meta-analysis.","volume":"16","author":"Z Anywaine","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0012011.ref006","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.antiviral.2012.06.001","article-title":"Molecular biology and genetic diversity of Rift Valley fever virus","volume":"95","author":"T. Ikegami","year":"2012","journal-title":"Antiviral Res"},{"issue":"1","key":"pntd.0012011.ref007","doi-asserted-by":"crossref","first-page":"e0009852","DOI":"10.1371\/journal.pntd.0009852","article-title":"Paving the way for human vaccination against Rift Valley fever virus: A systematic literature review of RVFV epidemiology from 1999 to 2021.","volume":"16","author":"KN Gerken","year":"2022","journal-title":"PLoS Negl Trop Dis."},{"issue":"029","key":"pntd.0012011.ref008","article-title":"Rift Valley fever virus: movement of infected humans threatens global public health and agriculture.","volume":"17","author":"S Gibson","year":"2022","journal-title":"CABI Reviews."},{"issue":"5","key":"pntd.0012011.ref009","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1099\/jgv.0.000765","article-title":"Rift Valley fever virus: strategies for maintenance, survival and vertical transmission in mosquitoes","volume":"98","author":"S Lumley","year":"2017","journal-title":"J Gen Virol"},{"issue":"3","key":"pntd.0012011.ref010","article-title":"Perspectives of Next-Generation Live-Attenuated Rift Valley Fever Vaccines for Animal and Human Use.","volume":"11","author":"PJ Wichgers Schreur","year":"2023","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"pntd.0012011.ref011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41541-023-00769-w","article-title":"Advancements in Rift Valley fever vaccines: a historical overview and prospects for next generation candidates.","volume":"8","author":"C Alkan","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"4","key":"pntd.0012011.ref012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"R Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"pntd.0012011.ref013","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1128\/JVI.75.3.1371-1377.2001","article-title":"Genetic evidence for an interferon-antagonistic function of rift valley fever virus nonstructural protein NSs","volume":"75","author":"M Bouloy","year":"2001","journal-title":"J Virol"},{"issue":"3","key":"pntd.0012011.ref014","doi-asserted-by":"crossref","first-page":"e0004550","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths.","volume":"10","author":"B Makoschey","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"issue":"6","key":"pntd.0012011.ref015","doi-asserted-by":"crossref","first-page":"e2874","DOI":"10.1371\/journal.pntd.0002874","article-title":"Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model","volume":"8","author":"KA Dodd","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"pntd.0012011.ref016","doi-asserted-by":"crossref","DOI":"10.3390\/v14112470","article-title":"Intranasal Exposure to Rift Valley Fever Virus Live-Attenuated Strains Leads to High Mortality Rate in Immunocompetent Mice.","volume":"14","author":"S Lacote","year":"2022","journal-title":"Viruses"},{"issue":"Pt 10","key":"pntd.0012011.ref017","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development","volume":"66","author":"H Caplen","year":"1985","journal-title":"J Gen Virol"},{"issue":"14","key":"pntd.0012011.ref018","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift Valley Fever Virus MP-12 Vaccine Is Fully Attenuated by a Combination of Partial Attenuations in the S, M, and L Segments","volume":"89","author":"T Ikegami","year":"2015","journal-title":"J Virol"},{"issue":"6","key":"pntd.0012011.ref019","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","article-title":"Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate","volume":"16","author":"T. Ikegami","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"12","key":"pntd.0012011.ref020","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human Rift Valley fever.","volume":"19","author":"T. Ikegami","year":"2019","journal-title":"Expert Opinion on Biological Therapy"},{"issue":"4","key":"pntd.0012011.ref021","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.vaccine.2015.12.030","article-title":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","volume":"34","author":"PR Pittman","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"pntd.0012011.ref022","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.vaccine.2015.11.078","article-title":"Rift Valley fever MP-12 vaccine Phase 2 clinical trial: Safety, immunogenicity, and genetic characterization of virus isolates","volume":"34","author":"PR Pittman","year":"2016","journal-title":"Vaccine"},{"issue":"5","key":"pntd.0012011.ref023","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.4269\/ajtmh.22-0356","article-title":"Estimation of the Minimal Rift Valley Fever Virus Protective Neutralizing Antibody Titer in Human Volunteers Immunized with MP-12 Vaccine Based on Protection in a Mouse Model of Disease","volume":"107","author":"DM Watts","year":"2022","journal-title":"Am J Trop Med Hyg"},{"issue":"17","key":"pntd.0012011.ref024","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens.","volume":"28","author":"G Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"pntd.0012011.ref025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.vetmic.2016.09.009","article-title":"Mouse model for the Rift Valley fever virus MP12 strain infection","volume":"195","author":"Y Lang","year":"2016","journal-title":"Vet Microbiol"},{"issue":"5","key":"pntd.0012011.ref026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/jir.1991.11.297","article-title":"Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey","volume":"11","author":"JC Morrill","year":"1991","journal-title":"J Interferon Res"},{"issue":"1\u20132","key":"pntd.0012011.ref027","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetmic.2014.04.007","article-title":"Evaluation of lamb and calf responses to Rift Valley fever MP-12 vaccination","volume":"172","author":"WC Wilson","year":"2014","journal-title":"Vet Microbiol"},{"issue":"1","key":"pntd.0012011.ref028","first-page":"95","article-title":"Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep.","volume":"69","author":"P Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"issue":"3","key":"pntd.0012011.ref029","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.vaccine.2012.10.118","article-title":"Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep","volume":"31","author":"JC Morrill","year":"2013","journal-title":"Vaccine"},{"issue":"8","key":"pntd.0012011.ref030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00669-19","article-title":"Lethal Mutagenesis of Rift Valley Fever Virus Induced by Favipiravir","volume":"63","author":"B Borrego","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pntd.0012011.ref031","doi-asserted-by":"crossref","DOI":"10.3390\/v13040542","article-title":"The Change P82L in the Rift Valley Fever Virus NSs Protein Confers Attenuation in Mice.","volume":"13","author":"B Borrego","year":"2021","journal-title":"Viruses"},{"key":"pntd.0012011.ref032","doi-asserted-by":"crossref","first-page":"104703","DOI":"10.1016\/j.antiviral.2019.104703","article-title":"The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 1: Potential effects on adaptive immunity and response to vaccination.","volume":"174","author":"EC Clarke","year":"2020","journal-title":"Antiviral Res"},{"key":"pntd.0012011.ref033","doi-asserted-by":"crossref","first-page":"104702","DOI":"10.1016\/j.antiviral.2019.104702","article-title":"The use of mice lacking type I or both type I and type II interferon responses in research on hemorrhagic fever viruses. Part 2: Vaccine efficacy studies.","volume":"174","author":"M Zivcec","year":"2020","journal-title":"Antiviral Res"},{"key":"pntd.0012011.ref034","first-page":"621463","article-title":"A Hyper-Attenuated Variant of Rift Valley Fever Virus Generated by a Mutagenic Drug (Favipiravir) Unveils Potential Virulence Markers.","volume":"11","author":"B Borrego","year":"2020","journal-title":"Microbiol"},{"issue":"12","key":"pntd.0012011.ref035","doi-asserted-by":"crossref","first-page":"e0008942","DOI":"10.1371\/journal.pntd.0008942","article-title":"Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge.","volume":"14","author":"S Moreno","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0012011.ref036","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/JVI.80.6.2933-2940.2006","article-title":"Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene","volume":"80","author":"T Ikegami","year":"2006","journal-title":"J Virol"},{"issue":"1","key":"pntd.0012011.ref037","doi-asserted-by":"crossref","DOI":"10.3390\/v16010087","article-title":"Safety and Efficacy upon Infection in Sheep with Rift Valley Fever Virus ZH548-rA2, a Triple Mutant Rescued Virus.","volume":"16","author":"S Moreno","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"pntd.0012011.ref038","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.virusres.2012.07.019","article-title":"Detection and identification of Rift Valley fever virus in mosquito vectors by quantitative real-time PCR","volume":"169","author":"D Mwaengo","year":"2012","journal-title":"Virus Res"},{"issue":"4","key":"pntd.0012011.ref039","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4103\/0976-500X.119726","article-title":"How to calculate sample size in animal studies?","volume":"4","author":"J Charan","year":"2013","journal-title":"J Pharmacol Pharmacother"},{"issue":"2","key":"pntd.0012011.ref040","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.virol.2010.08.016","article-title":"The pathogenesis of Rift Valley fever virus in the mouse model","volume":"407","author":"DR Smith","year":"2010","journal-title":"Virology"},{"issue":"1\u20132","key":"pntd.0012011.ref041","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.virol.2012.05.012","article-title":"Ultrastructural study of Rift Valley fever virus in the mouse model","volume":"431","author":"C Reed","year":"2012","journal-title":"Virology"},{"issue":"1","key":"pntd.0012011.ref042","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1146\/annurev-virology-091919-065806","article-title":"Advances in Understanding Neuropathogenesis of Rift Valley Fever Virus.","volume":"9","author":"KA Connors","year":"2022","journal-title":"Annu Rev Virol."},{"issue":"6","key":"pntd.0012011.ref043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1051\/vetres\/2010033","article-title":"Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.","volume":"41","author":"M Pepin","year":"2010","journal-title":"Vet Res"},{"issue":"6","key":"pntd.0012011.ref044","doi-asserted-by":"crossref","first-page":"e2237","DOI":"10.1371\/journal.pntd.0002237","article-title":"Aedes mosquito saliva modulates Rift Valley fever virus pathogenicity.","volume":"7","author":"A Le Coupanec","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0012011.ref045","doi-asserted-by":"crossref","first-page":"e2156","DOI":"10.1371\/journal.pntd.0002156","article-title":"Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development.","volume":"7","author":"C Reed","year":"2013","journal-title":"PLoS Negl Trop Dis."},{"issue":"1","key":"pntd.0012011.ref046","first-page":"3","article-title":"Type I interferon receptor knockout mice as models for infection of highly pathogenic viruses with outbreak potential","volume":"39","author":"G Wong","year":"2018","journal-title":"Zool Res"},{"key":"pntd.0012011.ref047","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/978-1-60327-353-4_2","article-title":"Overcoming inhibition in real-time diagnostic PCR","volume":"943","author":"J Hedman","year":"2013","journal-title":"Methods Mol Biol"},{"issue":"1","key":"pntd.0012011.ref048","article-title":"MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses.","volume":"8","author":"E Lopez-Gil","year":"2020","journal-title":"Vaccines (Basel)."},{"issue":"1","key":"pntd.0012011.ref049","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41541-022-00551-4","article-title":"Immune correlates of protection following Rift Valley fever virus vaccination.","volume":"7","author":"JD Doyle","year":"2022","journal-title":"NPJ VaccinesPubMed Central PMCID"},{"issue":"7","key":"pntd.0012011.ref050","doi-asserted-by":"crossref","first-page":"e1010649","DOI":"10.1371\/journal.ppat.1010649","article-title":"Genetic diversity of collaborative cross mice enables identification of novel rift valley fever virus encephalitis model.","volume":"18","author":"HN Cartwright","year":"2022","journal-title":"PLoS Pathog."}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0012011","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T18:06:43Z","timestamp":1724954803000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0012011"}},"subtitle":[],"editor":[{"given":"Mabel","family":"Carabali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":50,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0012011","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.20.581149","asserted-by":"object"}]},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}